Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;144(1):109002.
doi: 10.1016/j.ymgme.2024.109002. Epub 2024 Dec 16.

Feasibility of newborn screening for pyridoxine-dependent epilepsy

Kristine Pauly  1 , Michael Woontner  1 , Jose E Abdenur  2 , Bimal P Chaudhari  3 , Rachel Gosselin  4 , Kimberly A Kripps  5 , Janet A Thomas  1 , Michael F Wempe  6 , Sidney M Gospe Jr  7 , Curtis R Coughlin 2nd  8
Affiliations

Feasibility of newborn screening for pyridoxine-dependent epilepsy

Kristine Pauly et al. Mol Genet Metab. 2025 Jan.

Abstract

Background: Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is a developmental epileptic encephalopathy historically characterized by seizures that are resistant to antiseizure medications. Treatment with pyridoxine and lysine reduction therapies are associated with seizure control and improved developmental outcomes. In rare circumstances, patients have died prior to diagnosis and treatment with pyridoxine, and many patients are diagnosed after six months of age when lysine reduction therapies have limited efficacy. Recently two new metabolites were identified (2S,6S-/2S,6R-oxopropylpiperidine-2-carboxylic acid, 2-OPP and 6-oxo-pipecolate, 6-oxo-pip), and we evaluated these metabolites as potential newborn screening biomarkers.

Methods: We recruited participants with a confirmed diagnosis of PDE-ALDH7A1 and retrieved their residual dried blood spots from state-sponsored newborn screening programs. We evaluated the dried blood spots for 2-OPP using commercially available newborn screening kits and equipment, and developed a second-tier test for 6-oxo-pip using LC-MS/MS.

Results: We received eight residual dried blood spots collected before the onset of seizures and the diagnosis of PDE-ALDH7A1. In our newborn screening experiments, 2-OPP was elevated in 7 of 8 samples from affected participants with a mean of 3.08 μmol/L (95 % CI 2.17-3.99) compared to a mean of 0.09 μmol/L (95 % CI 0.09-0.10) in controls (p < 0.001). Second tier testing demonstrated elevated 6-oxo-pip in all samples from affected participants with a mean of 5.66 μmol/L (95 % CI 1.51-9.81) and was undetectable in controls (p < 0.001).

Conclusion: Patients with PDE-ALDH7A1 can be identified using neonatal dried blood spots prior to the onset of symptoms. The use of commercially available newborn screening approaches demonstrates the feasibility of newborn screening for this treatable condition.

Keywords: 6-oxo-pipecolate; ALDH7A1; Newborn screening; PDE-ALDH7A1; Pyridoxine-dependent epilepsy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

References

    1. Hunt AD, Stokes J, McCRORY WW, Stroud HH, Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine, Pediatrics 13 (1954) 140–145. - PubMed
    1. Basura GJ, Hagland SP, Wiltse AM, Gospe SM, Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 north American cases submitted to a patient registry, Eur. J. Pediatr. 168 (2009) 697–704. - PubMed
    1. Falsaperla R, et al. , Pyridoxine-dependent epilepsies: an observational study on clinical, diagnostic, therapeutic and prognostic features in a pediatric cohort, Metab. Brain Dis. 33 (2018) 261–269. - PubMed
    1. Falsaperla R, et al. , PYRIDOXINE-dependent epilepsy (PDE): an observational study of neonatal cases on the role of pyridoxine in patients treated with standard anti-seizure medications, Seizure 118 (2024) 156–163. - PubMed
    1. van Karnebeek CDM, et al. , Pyridoxine-dependent epilepsy: an expanding clinical spectrum, Pediatr. Neurol. 59 (2016) 6–12. - PubMed

Supplementary concepts